ARTICLE | Finance

Regulatory Milestones

Highlights of weekly biotech stock moves

November 22, 2010 8:00 AM UTC

Amgen Inc. (NASDAQ:AMGN) gained $0.53 to $55 last week after FDA approved an sBLA for Xgeva denosumab to prevent skeletal-related events in patients with bone metastases from solid tumors (see " Full Speed Ahead," A15).

Amgen also was the subject of media rumors last week, suggesting it might bid to acquire Actelion Ltd. (SIX:ATLN). The Swiss biotech, which gained CHF6.20 (12%) to CHF56.45 on the week, said it is in "regular dialogue with other industry participants." Earlier this month, Actelion declined to comment on rumors it had formed a special board committee to evaluate strategic alternatives, including a potential sale...